DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
DarioHealth Corp.NASDAQ: DRIO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$6.52M, compared with -$8.15M a year earlier. Trailing-twelve-month EBITDA was -$32.19M.
Context
- EBITDA amounted to 155.2% of revenue in FY2025, up 18.0 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$202.26M (-483.0%) for the fiscal year ending Dec 2026, a slowdown from the +6.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.52M+23.7% QoQ
- Last fiscal yearDec 2025
- -$34.69M+6.4% YoY
- LTMMar 2026
- -$32.19M+21.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +20.0% | -15.7% | -35.7 pp |
| 1 year | +6.4% | -483.0% | -489.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (34.69M) USD
- Year-over-year change
- +6.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (34.69M) | +6.4% |
| FY2024 | 2024-12-31 | (37.08M) | +31.8% |
| FY2023 | 2023-12-31 | (54.38M) | +2.2% |
| FY2022 | 2022-12-31 | (55.6M) | +20.6% |
| FY2021 | 2021-12-31 | (70.02M) | — |
EBITDA vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 EBITDA of -$32.19M is the 5th highest of the 11 companies compared; the peer median is -$82.56M.
- Its year-over-year change of +21.9% is the 6th highest of 11, against a peer median of +19.9%.
- EBITDA amounts to 151.9% of revenue for DRIO, versus a peer median of 53.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $94.51M | +693.8% | — | 11.5% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $6.51M | +153.6% | -13.4% | 66.7% |
| LTM Mar 2026 | $4.36M | +191.5% | -28.5% | 0.5% | |
| LTM Mar 2026 | -$21.6M | +93.7% | — | 3.0% | |
| LTM Mar 2026 | -$32.19M | +21.9% | — | 151.9% | |
| LTM Mar 2026 | -$58.51M | -133.4% | — | 18.3% | |
| LTM Mar 2026 | -$106.6M | +54.1% | — | 66.6% | |
| LTM Mar 2026 | -$106.84M | -14.3% | — | 5818.9% | |
| LTM Mar 2026 | -$191.95M | -32.3% | — | 387.1% | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| Peer median (excluding DRIO) | -$82.56M | +19.9% | -21.0% | 53.5% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M |
| Cost of Revenue | 12.44M | 18M | 14.37M | 13.77M | 9.69M |
| Gross Profit | 8.07M | 9.66M | 5.98M | 13.27M | 12.67M |
| Gross Margin | 39.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Research & Development | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M |
| Selling, General & Admin | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M |
| Operating Expenses | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M |
| EBITDA | (70.02M) | (55.6M) | (54.38M) | (37.08M) | (34.69M) |
| EBITDA Margin | -341.3% | -201.0% | -267.2% | -137.1% | -155.2% |
| Operating Income | (76.49M) | (56.81M) | (56.19M) | (57.74M) | (36.66M) |
| Operating Margin | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Interest Income | 44K | 506K | 1.87M | 1.12M | 943K |
| Interest Expense | 84K | 2.68M | 645K | 96K | 3.36M |
| Other Income / Expenses | (235K) | (5.38M) | (3.17M) | 13.15M | (4.95M) |
| Income Before Tax | (76.73M) | (62.19M) | (59.36M) | (44.6M) | (41.61M) |
| Pre-Tax Margin | -374.1% | -224.9% | -291.7% | -164.9% | -186.1% |
| Income Tax Expense | 32K | 4K | 64K | (1.85M) | 105K |
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Net Margin | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (Basic) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| EPS (Diluted) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| Weighted Avg Shares | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
| Weighted Avg Shares (Diluted) | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.